Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 15, 2018 - Issue 8
Submit an article Journal homepage
11,199
Views
7
CrossRef citations to date
0
Altmetric
Editorial

Designing inhaled protein therapeutics for topical lung delivery: what are the next steps?

Elsa Bodier-MontagutelliCentre d'Etude des Pathologies Respiratoires, Université de Tours, Tours, France;Centre d'Etude des Pathologies Respiratoires, U1100, INSERM, Centre d’Etude des Pathologies Respiratoires, Tours, France;CHRU de Tours, Service de Pharmacie, Tours, FranceView further author information
,
Alexie MayorCentre d'Etude des Pathologies Respiratoires, Université de Tours, Tours, France;Centre d'Etude des Pathologies Respiratoires, U1100, INSERM, Centre d’Etude des Pathologies Respiratoires, Tours, France;Formulation Development Unit – Biotherapeutics, Sanofi Aventis Recherche Développement, Vitry-sur-Seine, FranceView further author information
,
Laurent VecellioCentre d'Etude des Pathologies Respiratoires, Université de Tours, Tours, France;Centre d'Etude des Pathologies Respiratoires, U1100, INSERM, Centre d’Etude des Pathologies Respiratoires, Tours, FranceView further author information
,
Renaud RespaudCentre d'Etude des Pathologies Respiratoires, Université de Tours, Tours, France;Centre d'Etude des Pathologies Respiratoires, U1100, INSERM, Centre d’Etude des Pathologies Respiratoires, Tours, France;CHRU de Tours, Service de Pharmacie, Tours, FranceView further author information
&
Nathalie Heuzé-Vourc’hCentre d'Etude des Pathologies Respiratoires, Université de Tours, Tours, France;Centre d'Etude des Pathologies Respiratoires, U1100, INSERM, Centre d’Etude des Pathologies Respiratoires, Tours, FranceCorrespondence[email protected]
View further author information
Pages 729-736 | Received 31 May 2018, Accepted 18 Jul 2018, Published online: 27 Jul 2018

References

  • Sécher T, Guilleminault L, Reckamp K, et al. Therapeutic antibodies: a new era in the treatment of respiratory diseases? Pharmacol Ther. 2018 published online 2018 May 4. DOI:10.1016/j.pharmthera.2018.05.003.
  • Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281:23514–23524.
  • Guilleminault L, Azzopardi N, Arnoult C, et al. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J Control Release. 2014;196:344–354.
  • de Boer AH, Hagedoorn P, Hoppentocht M, et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017;14:499–512.
  • Carvalho TC, McConville JT. The function and performance of aqueous aerosol devices for inhalation therapy. J Pharm Pharmacol. 2016;68:556–578.
  • Respaud R, Vecellio L, Diot P, et al. Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Deliv. 2015;12:1027–1039.
  • Hertel SP, Winter G, Friess W. Protein stability in pulmonary drug delivery via nebulization. Adv Drug Deliv Rev. 2015;93:79–94.
  • Pritchard JN, Hatley RH, Denyer J, et al. Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments. Ther Deliv. 2018;9:121–136.
  • Van Heeke G, Allosery K, De Brabandere V, et al. Nanobodies as inhaled biotherapeutics for lung diseases. Pharmacol Ther. 2017;169:47–56.
  • Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev. 2014;75:81–91.
  • Respaud R, Marchand D, Parent C, et al. Effect of formulation on the stability and aerosol performance of a nebulized antibody. MAbs. 2014;6:1347–1355.
  • Filipe V, Jiskoot W, Basmeleh AH, et al. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. MAbs. 2012;4:740–752.
  • Guillon A, Sécher T, Dailey LA, et al. Insights on animal models to investigate inhalation therapy: relevance for biotherapeutics. Int J Pharm. 2018;536:116–126.
  • Röhm M, Carle S, Maigler F, et al. A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery. Int J Pharm. 2017;532(1):537–546.
  • Doryab A, Amoabediny G, Salehi-Najafabadi A. Advances in pulmonary therapy and drug development: lung tissue engineering to lung-on-a-chip. Biotechnol Adv. 2015;34:588–596.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.